Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: Investigation using human peripheral monocytes

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 12, 2001, Pages 1679-1685

  Kato, Miyako ^a   Nishida, Shinichi ^a   Kitasato, Hidero ^a,b   Sakata, Natsue ^a   Kawai, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 6 METHOXY 2 NAPHTHYLACETIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DRUG METABOLITE; ETODOLAC; IBUPROFEN; INDOMETACIN; LIPOPOLYSACCHARIDE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; S 2474; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CELL STIMULATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MONOCYTE; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0035671557     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011778070     Document Type: Article

References (35)

1. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
2. Inducible cyclooxygenase (COX-2): A safer therapeutic target?
3. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
4. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
5. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids
6. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
7. Safety of meloxicam: A global analysis of clinical trials
8. Clinical implications of selective cyclooxygenase-2 inhibition
9. Effects of anti-inflammatory drugs on prostaglandin biosynthesis
10. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
11. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and Cox 2 inhibitors
12. Novel antiarthritic agents with 1,2-isothiazolidine-1, 1-dioxide (γ-sultam) skeleton: Cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase
13. Cyclooxygenase selectivity and the risk of gastrointestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration
14. Interaction of RU 486, a glucocorticoid and progestin antagonist with human circulating mononuclear leukocytes
15. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells
16. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
17. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
18. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa
19. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
20. Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors
21. Gastrointestinal tolerability of meloxicam and piroxicam: A double-blind placebo-controlled study
22. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
23. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2
24. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
25. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib)
26. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
27. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
28. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
29. Pharmacological analysis of cyclooxygenase-1 in inflammation
30. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
31. Mechanism of action of anti-inflammatory drugs
32. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
33. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
34. 2 production following its intracellular conversion into cyclooxygenase inhibitors
35. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells